Blossom Biosciences
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Blossom Biosciences - overview
Established
2021
Location
Beijing, -, China
Primary Industry
Pharmaceuticals
About
Based in Beijing, China and established in 2021, Bosheng Pharmaceutical is a medical company that focuses on drug development. The company was co-founded by Osprey Asset Management and Hansen Pharmaceutical Group. The company is committed to bringing potential breakthrough therapeutics to more patients in China, and Dr. Andrew Phillips, Managing Director of Fishhawk Capital Management and former CEO of C4 Therapeutics, Inc.
is now acting CEO of the company. In June 2021, it closed a round of USD 72 million series A funding. The company focuses on the development of therapeutic drugs and offers a full range of molecular and cell biology research methods, including mammalian cell culture, transfection, cell viability assays, IC50/EC50 studies, apoptosis, molecular cloning, WesternBlot and ELISA assays.
Current Investors
Cormorant Asset Management, Hansoh Pharmaceutical
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Company Stage
Series A
Total Amount Raised
Subscriber access only
Blossom Biosciences - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.